EUVIMEDEUVIMED entdecken
Crossref

Targeting brain injury in sepsis: how remimazolam modulates the TLR4/NF-κB pathway in rats

Quan-Hui Dong, Xiao-Shi Liu, Shu-Ting Liu, Quan Chen

Folia Neuropathologica · 2025

DOI: 10.5114/fn.2025.152999 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Neuropathologica, 2025. Verfasst von Quan-Hui Dong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate College of Jinzhou Medical University, Fushun 121001, China. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, NF-kappa B, Sepsis, Brain Injuries.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sepsis-associated brain injury can lead to severe neurobehavioral and cognitive impairments due to inflammation, oxidative stress, and blood-brain barrier (BBB) dysfunction. Remimazolam (RM), a novel benzodiazepine, may have therapeutic potential for managing these complications. This study aimed to explore the therapeutic effects and potential molecular mechanisms of RM on BBB injury and brain injury in septic rats. Septic rat models were constructed using cecal ligation and puncture (CLP), with 75 rats randomly assigned to five groups (15 rats per group). RM (5 mg/kg, 10 mg/kg, and 20 mg/kg) was injected intraperitoneally to treat the rats. Neurobehavioral and cognitive functions were evaluated via neurological scores, water maze, and Y-maze tests. Brain water content was measured using the dry-wet weight method, and BBB permeability was assessed with Evans blue staining. Oxidative stress and inflammatory markers were detected using enzyme-linked immunosorbent assays and biochemical kits. Western blot analysis was performed to evaluate RM's effects on TLR4/NF-κB pathway proteins. RM treatment alleviated neurobehavioral and cognitive dysfunction while reducing inflammation and oxidative stress in septic rat brain tissue, with 10 mg/kg RM showing the greatest efficacy. RM also reduced brain water content and BBB damage, downregulating TLR4/NF-κB pathway proteins. These findings suggest that RM can effectively alleviate blood-brain barrier and brain injury in septic rats by inhibiting the TLR4/NF-κB pathway. The therapeutic effects observed may pave the way for future clinical research into RM's use for managing sepsis-associated brain injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 4NF-kappa BSepsisBrain InjuriesAnimalsRatsMaleBlood-Brain BarrierSignal TransductionOxidative StressRats, Sprague-DawleyDisease Models, Animal

Stichwörter der Autor:innen

TTLR4/NF-κB pathwayblood-brain barrier damagebrain damagesepsisremimazolam

Substanzen

Toll-Like Receptor 4NF-kappa BTlr4 protein, rat

Autor:innen und Institutionen

  • Graduate College of Jinzhou Medical University, Fushun 121001, China.
  • Department of Anesthesiology, Fushun Mining Bureau General Hospital of Liaoning Health Industry Group, Fushun 113001, China.
  • Department of Anesthesiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.

Zitieren

APA

Dong, Q. H., Liu, X. S., Liu, S. T., & Chen, Q. (2025). Targeting brain injury in sepsis: how remimazolam modulates the TLR4/NF-κB pathway in rats. Folia Neuropathologica. https://doi.org/10.5114/fn.2025.152999

Vancouver

Dong QH, Liu XS, Liu ST, Chen Q. Targeting brain injury in sepsis: how remimazolam modulates the TLR4/NF-κB pathway in rats. Folia Neuropathologica. 2025. doi:10.5114/fn.2025.152999

BibTeX
@article{Dong2025,
  author = {Dong, Quan-Hui and Liu, Xiao-Shi and Liu, Shu-Ting and Chen, Quan},
  title = {Targeting brain injury in sepsis: how remimazolam modulates the TLR4/NF-κB pathway in rats},
  journal = {Folia Neuropathologica},
  year = {2025},
  doi = {10.5114/fn.2025.152999}
}
Kostenlos starten →